Asset Details
Do you wish to reserve the book?
Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide : a meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide : a meta-analysis
Do you wish to request the book?
Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide : a meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide : a meta-analysis
2012
Overview
In the global Fracture Prevention Trial, teriparatide reduced the risk of vertebral and non-vertebral fractures and significantly increased BMD. Recently, a 12-month, phase 3, randomized, multicenter, double-blind, placebo-controlled trial with BMD as a primary endpoint was conducted to assess the effects of teriparatide in Japanese subjects at high risk of fracture. Although BMD was significantly increased in the Japanese study, the study was not statistically powered to assess the anti-fracture efficacy with teriparatide treatment. A meta-analysis was carried out testing whether teriparatide had consistent anti-fracture efficacy in Japanese patients compared to that observed in the global fracture trial. Three studies in which fracture data were available from prospectively scheduled spinal radiographs were included in the analysis. A systematic review of the literature (Medline, Embase) confirmed that no studies with teriparatide had been excluded from this analysis. There was no significant heterogeneity for vertebral and non-vertebral fractures among the studies included in the meta-analysis. Odds ratio estimates (95% CI) were 0.29 (0.20, 0.43) for vertebral fracture and 0.53 (0.32, 0.86) for non-vertebral fracture. There was also a consistent effect of teriparatide to increase BMD across all studies. Furthermore, our analysis demonstrated that teriparatide-mediated increases in spine BMD accounted for 25–32% of the reduction in vertebral fracture risk in the combined population including Caucasian and Japanese patients, which was similar to that derived from Caucasian patients. These results provide evidence for the consistency of anti-fracture efficacy with teriparatide treatment in Japanese patients compared to those observed in Caucasian patients.
Publisher
Springer Japan,Springer,Springer Nature B.V
Subject
/ Asian Continental Ancestry Group
/ Biological and medical sciences
/ Bone Density Conservation Agents - pharmacology
/ Bone Density Conservation Agents - therapeutic use
/ Diseases of the osteoarticular system
/ European Continental Ancestry Group
/ Female
/ Fracture
/ Fractures, Bone - complications
/ Fractures, Bone - drug therapy
/ Fractures, Bone - physiopathology
/ Fractures, Bone - prevention & control
/ Humans
/ Injuries of the limb. Injuries of the spine
/ Japan
/ Male
/ Medicine
/ Osteoporosis - complications
/ Osteoporosis - physiopathology
/ Osteoporosis. Osteomalacia. Paget disease
/ Spinal Fractures - complications
/ Spinal Fractures - drug therapy
/ Spinal Fractures - physiopathology
/ Spinal Fractures - prevention & control
